Abstract 586P
Background
Mobocertinib is the first oral tyrosine kinase inhibitor approved to treat epidermal growth factor receptor (EGFR) exon 20 insertion mutation positive (ex20ins+) NSCLC. Traditional PCR detects a limited number of EGFR ex20ins variants, identifying ≤50% of pts with EGFR ex20ins. The AmoyDx Pan Lung Cancer PCR panel is a real-time mPCR assay for qualitative detection of alterations in 11 driver genes, including EGFR. Here we assess methods to detect EGFR ex20ins, compare mobocertinib efficacy in pts tested for EGFR ex20ins using these methods, and analyze EGFR ex20ins detection coverage using real-world datasets.
Methods
Pts were enrolled in the mobocertinib phase 1/2 study (NCT02716116) based on EGFR ex20ins detected by various local tissue or liquid clinical trial assays (CTAs). In this analysis, baseline tissue samples were evaluated for EGFR ex20ins status using AmoyDx mPCR. Pt samples from the phase 1/2 trial (n=57) and those from commercially acquired with NSCLC (n=10) were used to determine concordance between mPCR and CTAs. Efficacy analyses were performed in platinum-pretreated pts (PPP; N=114 [FDA-approved population]) with EGFR ex20ins+ NSCLC) from the trial. Retrospective analysis was conducted in pts with NSCLC who had confirmed EGFR ex20ins using 1 global clinical trial and 4 real-world data sources.
Results
We found concordance between mPCR assessment and CTAs in samples from the CTA EGFR ex20ins-positive (n=52) and CTA EGFR ex20ins-negative populations (n=10) tested by mPCR. Point estimates of positive and negative percentage agreement (95% confidence interval) were 91.2% (80.7%–97.1%) and 100% (69.2%–100%), respectively. Response-evaluable pts who tested EGFR ex20ins+ by mPCR (n=50) had a confirmed objective response rate of 28.0% and a disease control rate of 80.0% on mobocertinib. In the retrospective analysis, mPCR identified EGFR ex20ins in an estimated 79.0% (502/636) of pts.
Conclusions
The AmoyDx mPCR assay performed better than traditional PCR and effectively identified pts with EGFR ex20ins+ NSCLC who may benefit from mobocertinib therapy, providing a fast and effective diagnostic option to guide treatment.
Clinical trial identification
NCT02716116, 3/23/2016.
Editorial acknowledgement
Professional medical writing assistance was provided by Corey Burgin, PhD, of Peloton Advantage, LLC, an OPEN Health company.
Legal entity responsible for the study
Takeda Development Center Americas, Inc.
Funding
This study was funded by Takeda Development Center Americas, Inc., Lexington, MA, USA.
Disclosure
C. Zhou: Financial Interests, Personal, Other, Lecturing: Eli Lilly China, Sanofi, Roche, Merck Sharp & Dohme, Qilu, Hengrui, Innovent Biologics, Luye Pharma, TopAlliance Biosciences Inc, Amoy Diagnostics, CStone Pharmaceuticals. V. Bunn, M. Lin, J. Huang, J. Wang, R.J. Fram, S. Vincent, Y. Li: Financial Interests, Personal, Full or part-time Employment: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract